RedHill Biopharma (RDHL) Equity Ratio (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Equity Ratio for 3 consecutive years, with 0.26 as the latest value for Q4 2024.

  • Quarterly Equity Ratio fell 389.11% to 0.26 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 0.26 through Dec 2024, down 389.11% year-over-year, with the annual reading at 0.26 for FY2024, 389.11% down from the prior year.
  • Equity Ratio for Q4 2024 was 0.26 at RedHill Biopharma, down from 0.09 in the prior quarter.
  • The five-year high for Equity Ratio was 0.09 in Q4 2023, with the low at 0.3 in Q4 2022.
  • Average Equity Ratio over 3 years is 0.16, with a median of 0.26 recorded in 2024.
  • The sharpest move saw Equity Ratio surged 129.47% in 2023, then plummeted 389.11% in 2024.
  • Over 3 years, Equity Ratio stood at 0.3 in 2022, then surged by 129.47% to 0.09 in 2023, then tumbled by 389.11% to 0.26 in 2024.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.26, 0.09, and 0.3 for Q4 2024, Q4 2023, and Q4 2022 respectively.